

Freedom of Information Request: Our Reference CTHB_306_17

You asked:

Within your trust how many **intra-vitreous injections/implants** have been used in the latest 4 months, if possible between May and August 2017?

If your trust is able to identify **injections/implants** by eye conditions please split by the drug used [ranibizumab, bevacizumab, aflibercept, Fluocinolone and Dexamethasone].

	Lucentis (ranibizumab) Injections	Avastin (bevacizumab) Injections	Eylea (aflibercept) Injections	Iluvien (Fluocinolone) Implants	Ozudex (Dexamethasone) Implants
Total	704	0	580	0	22
<i>Wet Age Related Macular Degeneration (wAMD)</i>	432	0	400	0	0
<i>Diabetic Macular Oedema (DMO)</i>	168	0	118	0	11
<i>Retinal Vein Occlusion - Central or Branch (CRVO or BRVO)</i>	90	0	62	0	11
<i>Other eg mCNV</i>	14	0	0	0	0

Our response:

The table you have provided above has been populated with the number of intra-vitreous injections/implants administered during the period of May 2017 and August 2017, by medicine and by diagnosed eye condition.